Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

ClinicalTrials.gov ID: NCT00443872

Public ClinicalTrials.gov record NCT00443872. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications

Study identification

NCT ID
NCT00443872
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Parkinson's Disease and Movement Disorder Center of Boca Raton
Other
Enrollment
77 participants

Conditions and interventions

Interventions

  • orally disintegrating selegiline (Zelapar) Drug

Drug

Eligibility (public fields only)

Age range
30 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2007
Primary completion
Aug 31, 2008
Completion
Nov 30, 2008
Last update posted
Oct 30, 2014

2007 – 2008

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
University of California - Irvine Irvine California 92697
Coastal Neurological Medical Group, Inc La Jolla California 92037
University of Southern California Los Angeles California 90093
The Parkinson's Institute Sunnyvale California 94085
Parkinson's Disease and Movement Disorder Center of Boca Raton Boca Raton Florida 33486
University of South Florida Tampa Florida 33606
Methodist Plaza Speciality Clinic Des Moines Iowa 50309
University of Kansas Medical Center Kansas City Kansas 66160
Ochsner Clinic Foundation New Orleans Louisiana 70121
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Harvard Vanguard Medical Associates Boston Massachusetts 02215
Henry Ford Health Center - Franklin Pointe Southfield Michigan 48034
Struthers Parkinson's Center Golden Valley Minnesota 55427
University of Toledo Toledo Ohio 43614
NeuroHealth Parkinson Disease and Movement Disorder Center Warwick Rhode Island 02886
Neurology Specialists Dallas Dallas Texas 75231
ETMC Neurological Institute Tyler Texas 75701

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00443872, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 30, 2014 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00443872 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →